1. Home
  2. LEE vs ALXO Comparison

LEE vs ALXO Comparison

Compare LEE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

HOLD

Current Price

$7.69

Market Cap

173.8M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.94

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEE
ALXO
Founded
1890
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.8M
205.9M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
LEE
ALXO
Price
$7.69
$1.94
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
28.3K
618.0K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
$543,955,000.00
N/A
Revenue This Year
$5.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$1.02
52 Week High
$11.88
$2.66

Technical Indicators

Market Signals
Indicator
LEE
ALXO
Relative Strength Index (RSI) 35.53 42.12
Support Level $7.14 $1.56
Resistance Level $8.79 $2.17
Average True Range (ATR) 0.41 0.09
MACD -0.08 -0.02
Stochastic Oscillator 0.00 19.64

Price Performance

Historical Comparison
LEE
ALXO

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: